A CAR-T Win for Celgene (CELG) as Partner bluebird bio Releases 'Highly Promising' Results - Jefferies

Jefferies analyst Brian Abrahams weighed in on Celgene (NASDAQ: CELG) after partner bluebird bio posted 'highly promising' bb2121 results in multiple myeloma.

Abrahams commented, "Data emerging from BLUE’s bb2121 (CELG-partnered) looks highly promising; though it will need to be replicated in a much broader pop., safety needs to stay clean, and durability and manufacturing/cost feasibility are unknowns with the approach, we believe it provides strong validation for CELG’s anti-BCMA candidates, helps offset recent BD/pipeline skepticism, and supports CELG’s underappreciated, multi-faceted MM life cycle extension strategy. "

The firm maintained a Buy rating and price target of $140 on BLUE.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $118.51 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Prysmian SpA (PRY:IM) (PRYMY) PT Raised to EUR53 at HSBC
• TD Cowen Resumes EQT Corp. (EQT) at Hold